TDP-43, a multifunctional protein involved in RNA splicing, stability, and transport, has long been recognized as a pivotal player in neurodegenerative diseases. Its aggregation and cytoplasmic mislocalization have been documented across the majority of ALS and FTD cases, yet the precise consequences of its depletion at the molecular level have remained incompletely defined. Bryce-Smith and colleagues have now uncovered that TDP-43 loss leads to widespread activation of cryptic polyadenylation sites within pre-mRNA transcripts, resulting in truncated, aberrantly processed RNAs that may exert toxic effects or disrupt normal cellular function.

The concept of cryptic polyadenylation involves the utilization of unexpected polyadenylation signals within intronic or untranslated regions, which prematurely stop transcription and destabilize transcripts or alter their coding potential. This process had previously been suspected as a contributor to altered RNA landscapes in neurodegeneration, but direct causative links remained elusive. The current study rigorously demonstrates through RNA sequencing and molecular assays that TDP-43 normally suppresses these cryptic sites, maintaining transcriptome integrity. Loss of this suppression unleashes cryptic polyadenylation genome-wide, severely perturbing normal gene expression programs.

The investigative team employed state-of-the-art transcriptomic profiling of human neuronal models depleted of TDP-43, combined with post-mortem brain tissue analyses from ALS and FTD patients. This multi-tiered approach revealed a consistent signature of cryptic polyadenylation events correlating with disease pathology. Notably, many of the affected transcripts are linked to synaptic function, neuronal survival, and RNA metabolism, underscoring the profound impact of disrupted RNA processing on neurodegeneration. Through rigorous bioinformatics analysis, the researchers mapped these cryptic polyadenylation sites and identified conserved sequence motifs implicated in aberrant cleavage and polyadenylation.

Mechanistically, the loss of TDP-43 appears to dismantle a critical layer of post-transcriptional quality control that safeguards against premature transcript termination. Normally, TDP-43 binds to specific RNA motifs, masking cryptic polyadenylation signals and preserving full-length mRNA transcription. Without this protective interaction, cleavage and polyadenylation machinery erroneously recognize these cryptic sites, resulting in truncated transcripts lacking essential coding or regulatory elements. This disruption likely contributes not only to loss-of-function effects but may also provoke toxic gain-of-function from aberrant RNA species, amplifying neuronal vulnerability.

Beyond molecular characterization, Bryce-Smith et al. explored the functional repercussions of cryptic polyadenylation induction in neuronal models. Their results linked cryptic cleavage events to impaired neuronal differentiation, synaptic deficits, and decreased cell viability, recapitulating key neuropathological features of ALS and FTD. These findings demonstrate a direct pathophysiological consequence of disrupted RNA processing mediated by TDP-43 loss, bridging a critical gap between molecular pathology and cellular dysfunction.

This study’s implications extend beyond ALS/FTD, resonating broadly across neurodegenerative disorders where RNA-binding protein dysfunction is prevalent. The discovery that cryptic polyadenylation represents a widespread and underappreciated consequence of TDP-43 pathology metamorphoses our conceptual framework for RNA dysregulation in the nervous system. It highlights the intricate interplay between RNA-binding proteins and RNA processing machinery as a vital axis whose perturbation can precipitate neurodegeneration. Furthermore, the identification of cryptic polyadenylation as a targetable molecular event offers exciting opportunities for therapeutic innovation.

Intriguingly, the study also prompts a reevaluation of existing therapeutic strategies aimed at modulating TDP-43 expression or aggregation. While efforts have predominantly focused on preventing TDP-43 proteinopathies, the current findings suggest that restoring or mimicking TDP-43’s RNA regulatory functions may be equally critical. Approaches that prevent cryptic polyadenylation or stabilize full-length transcripts could counteract downstream pathological consequences, providing neuroprotection. The molecular signatures of cryptic polyadenylation may additionally serve as biomarkers for disease progression or treatment response.

The robust experimental design included rigorous controls and multiple validation steps, strengthening the credibility of the findings. Using CRISPR-mediated TDP-43 knockdown alongside RNA immunoprecipitation techniques, the authors convincingly demonstrated direct binding of TDP-43 to cryptic polyadenylation sites in normal cells. Complementary analyses in patient-derived neurons and post-mortem tissues further substantiated the translational relevance of the mechanism. This comprehensive approach exemplifies the power of integrating mechanistic molecular biology with clinically relevant models.

As neurodegenerative diseases continue to impose an enormous societal and medical burden, uncovering fundamental pathological cascades is imperative for progress. The elucidation of cryptic polyadenylation induced by TDP-43 loss enriches our mechanistic arsenal, providing a concrete target for future therapeutic development. While challenges remain in translating these molecular insights into clinical breakthroughs, the present findings invigorate the field with a novel disease paradigm grounded in RNA biology, promising hope for patients afflicted by ALS and FTD.

Future research will undoubtedly focus on identifying compounds or molecular tools capable of modulating cryptic polyadenylation processes. Investigating how this RNA processing dysregulation interacts with other pathological features such as protein aggregation, neuroinflammation, and mitochondrial dysfunction could uncover synergistic therapeutic strategies. Additionally, expanding the analysis to other cell types and stages of disease progression will clarify the temporal dynamics and cell specificity of cryptic polyadenylation, refining targeted interventions.

In summary, the study by Bryce-Smith and colleagues marks a significant advance in unraveling the RNA-based mechanisms underpinning ALS and FTD pathology. By revealing how TDP-43 safeguards transcriptome fidelity through suppression of cryptic polyadenylation, the research illuminates a critical vulnerability exploited in neurodegeneration. This work not only enhances our molecular understanding but also charts a compelling path forward for developing RNA-centric therapies that may transform outcomes for patients facing these relentless diseases.

Subject of Research: The molecular mechanisms by which TDP-43 loss induces cryptic polyadenylation and its contribution to neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Article Title: TDP-43 loss induces cryptic polyadenylation in ALS/FTD.

Article References:
Bryce-Smith, S., Brown, A.L., Chien, M.Z.Y.J. et al. TDP-43 loss induces cryptic polyadenylation in ALS/FTD. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02050-w

Image Credits: AI Generated

The crux of this new research lies in the revelation that the repeat expansion, previously thought to reside within an intron, is in fact aberrantly retained as part of an extended exon 1 through the employment of alternative splicing mechanisms. This exonization process involves the usage of downstream alternative 5′ splice sites, which effectively hijack the canonical splicing code to splice the intronic repeat expansion into mature mRNA transcripts. This insight overturns longstanding assumptions about how intronic expansions can influence cellular function, revealing a sophisticated layer of RNA processing that directly contributes to disease pathology.

Researchers employed an innovative technique termed “NRE-capture-seq” to selectively isolate and sequence RNAs containing the nucleotide repeat expansion (NRE) from patient-derived fibroblast and neuronal cultures. This powerful approach enabled the precise mapping of splice isoforms harboring the GGGGCC repeats, highlighting the heterogeneity and complexity of the aberrant splicing events. The ability to capture and analyze these rare, pathogenic transcripts in patient cells provides a valuable platform for understanding disease mechanisms at an unprecedented resolution.

Analysis of postmortem brain tissue from C9-ALS/FTD patients revealed that these aberrant splice isoforms accumulate in affected tissues. This accumulation underscores the pathological relevance of alternative splicing in driving disease progression. The finding that these extended exon 1 transcripts are not just cellular anomalies but critical contributors to disease expands the scope of therapeutic targets beyond protein aggregates to include the RNA processing machinery itself.

Central to the regulation of this aberrant splicing event is the serine/arginine-rich splicing factor 1 (SRSF1), a well-known RNA binding protein and splicing regulator. The study demonstrates that SRSF1 promotes the inclusion of the repeat expansion into the mRNA transcript by enhancing the usage of the alternative 5′ splice sites. This discovery places SRSF1 as a pivotal regulator of pathogenic RNA biogenesis in C9orf72-linked ALS/FTD, opening avenues for intervention at the level of splicing regulation.

The pathological significance of this mechanism extends beyond RNA processing to the toxic gain-of-function associated with DPR proteins. DPRs, generated through unconventional Repeat-Associated Non-AUG (RAN) translation of the expanded repeat RNA, accumulate in neuronal cytoplasm, exerting proteotoxic stress and contributing to neurodegeneration. By elucidating how the nuclearly retained intronic repeat segment gains access to cytoplasmic translation machinery as part of an extended exon, this study bridges a vital gap in understanding the integration of RNA biology and protein toxicity in ALS/FTD.

Therapeutically, these findings have immediate implications. Targeting SRSF1 with antisense oligonucleotides (ASOs) successfully reduced the abundance of aberrant splice isoforms and consequentially lowered DPR production in patient-derived cells. Similarly, ASOs designed to specifically bind and degrade the NRE-containing splice variants effectively diminished toxic protein levels. This dual-targeting strategy exemplifies precision medicine approaches aimed at rectifying the underlying RNA dysregulation driving disease.

Such advances in antisense technology showcase how manipulating RNA splicing events can translate into tangible therapeutic benefits. The capacity to modulate splicing factors and tailor transcript profiles offers a promising frontier in the treatment of complex neurodegenerative disorders, especially those where traditional protein-centric therapies have faltered. This study is emblematic of the potential held by RNA-centered interventions.

At a molecular level, the study sheds light on the alternative splice sites scattered downstream of the canonical exon 1 boundary. These cryptic 5′ splice sites, normally dormant, become aberrantly activated in the presence of the C9orf72 repeat expansion. This abnormal splice site selection highlights the plasticity of the splicing machinery and how genetic mutations can drastically remodel the transcriptomic landscape in disease conditions.

The notion that an intronic repeat can be exonized via alternative splicing provides a conceptual framework that may apply to other repeat expansion disorders. It suggests that RNA splicing alterations may represent a unifying pathological theme, wherein typically non-coding sequences are co-opted into coding regions, giving rise to new toxic entities. This paradigm shift could recalibrate ongoing research into RNA toxicity across a spectrum of neurodegenerative diseases.

The use of patient-derived neurons and fibroblasts in this research ensures that the observed molecular events reflect biologically relevant contexts, strengthening the translational applicability of the findings. Furthermore, the accumulation of these transcripts in postmortem brain tissues solidifies their pathological relevance in vivo, bridging in vitro mechanistic discoveries with clinical neuropathology.

Beyond the immediate ALS/FTD context, this work expands our understanding of RNA biology’s complexity in human disease. It highlights the intricacies of splicing regulation and how subtle perturbations can have dramatic consequences on cellular homeostasis. The interplay between splicing factors like SRSF1 and aberrant RNA sequences underlines the delicate balance cells must maintain to prevent disease.

The methodology adopted in this work—selective RNA capture combined with deep sequencing—establishes a benchmark for future studies aiming to dissect intricate RNA processing events in disease. It demonstrates how precise molecular tools can unravel the fine details of transcriptomic alterations that were previously inaccessible, paving the way for novel diagnostic and therapeutic strategies.

In summary, this landmark study reveals that aberrant splicing events exonize the C9orf72 hexanucleotide repeat expansion, reconciling how an intronic repeat is converted into a cytoplasmically translated toxic RNA species. By pinpointing SRSF1 as a key modulator and demonstrating that antisense oligonucleotides can effectively suppress pathogenic isoforms and reduce toxic DPR burden, the research sets a new course for therapeutic innovation in ALS/FTD. Such discoveries underscore the growing recognition of RNA processing defects as critical drivers of neurodegeneration and herald a new era of RNA-centric treatment modalities.

These insights not only deepen our comprehension of C9orf72-linked ALS and FTD but also inspire a reevaluation of splicing dysregulation in other repeat-expansion diseases, promising broad implications for neurobiology and medicine. As the field moves forward, strategies that integrate molecular genetics, RNA biology, and targeted therapeutics will likely transform the clinical landscape for patients afflicted with these devastating disorders.

Subject of Research: Aberrant splicing of the C9orf72 hexanucleotide repeat expansion in ALS/FTD and its role in the generation of toxic dipeptide repeat proteins.

Article Title: Aberrant splicing exonizes C9orf72 repeat expansion in ALS/FTD.

Article References:
Yang, S., Wijegunawardana, D., Sheth, U. et al. Aberrant splicing exonizes C9orf72 repeat expansion in ALS/FTD. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02039-5

Image Credits: AI Generated

ALS and FTD represent a spectrum of neurodegenerative diseases that share genetic and pathological overlaps, notably the presence of hexanucleotide repeat expansions in the C9orf72 gene. This mutation is the most common genetic cause of both conditions, leading to toxic gain-of-function effects via RNA foci and dipeptide repeat proteins, as well as loss-of-function consequences that impair vital cellular processes. The dual pathological mechanisms culminate in neuronal dysfunction and death, manifesting clinically as progressive paralysis in ALS and cognitive decline in FTD. Despite extensive research, effective therapies targeting the fundamental pathogenic drivers have remained elusive.

Dubey and Bellen’s research pivots attention to the lipid environment of neuronal membranes, specifically focusing on polyunsaturated fatty acids, which are essential components of cellular membranes and known to influence membrane fluidity, signaling pathways, and neuroinflammation. Their investigation elucidates how PUFAs may interact with pathways disrupted by the C9orf72 mutation, thereby conferring neuroprotection. This approach marks a departure from traditional emphasis on protein aggregates and RNA toxicity toward the modulation of lipid metabolism as a viable therapeutic strategy.

The study adopted a multifaceted methodology involving advanced lipidomics, cellular models derived from patient-induced pluripotent stem cells (iPSCs), and in vivo animal models harboring C9orf72 expansions. Through comprehensive lipid profiling, the researchers identified a significant alteration in the composition and metabolism of PUFAs in affected neurons compared with controls. Notably, there was a depletion of omega-3 and omega-6 fatty acids, implicating these molecules in the vulnerability of neurons to C9orf72-associated stress.

Further mechanistic exploration revealed that supplementation with specific PUFAs restored membrane integrity and reduced endoplasmic reticulum stress markers, which are known contributors to neurodegeneration. The restoration of membrane homeostasis appeared to ameliorate dysfunctional autophagy—a key cellular clearance process impaired in C9orf72 ALS/FTD—and decrease the accumulation of cytotoxic aggregates. These findings highlight the multifactorial benefits of PUFAs, extending beyond structural support to modulating critical cellular stress responses.

Intriguingly, the study also demonstrated that PUFAs influenced mitochondrial dynamics and bioenergetics in affected neurons. Given that mitochondrial dysfunction is a hallmark of ALS/FTD pathophysiology, this aspect underscores a broader systemic effect of lipid metabolism on neuronal survival. Treatment with PUFAs improved mitochondrial membrane potential and reduced reactive oxygen species production, thereby attenuating oxidative stress-induced cellular damage.

Neuropathological examination of C9orf72 animal models treated with PUFA-enriched diets corroborated the cellular findings. These animals exhibited delayed disease onset, improved motor function, and extended survival compared with untreated controls. The authors postulate that the neuroprotective effects arise from an integrated modulation of membrane composition, signaling cascades, and metabolic homeostasis, collectively contributing to resilience against the neurodegenerative cascade initiated by C9orf72 pathology.

The implications of this research transcend the immediate scope of C9orf72-linked ALS/FTD. The intersection between lipid biology and neurodegeneration could illuminate novel targets for a spectrum of disorders, including Alzheimer’s disease and Parkinson’s disease, where altered lipid metabolism is increasingly recognized as a contributor to pathogenesis. Dubey and Bellen’s work thereby opens a new frontier in neurotherapeutics centered on precision modulation of lipid profiles.

While the neuroprotective potential of PUFAs is promising, the study’s authors acknowledge that translation to clinical practice necessitates cautious optimization. Dosage, bioavailability, and timing of PUFA administration remain critical parameters to elucidate in human trials. Furthermore, the complexity of lipid metabolism networks mandates comprehensive systems-level analyses to predict and monitor therapeutic responses effectively.

Nevertheless, this study represents a paradigm shift toward integrative neurobiology, marrying genetic insights with metabolic regulation to confront the challenge of neurodegeneration. The burgeoning field of lipidomics stands to benefit profoundly from these findings, as researchers seek biomarkers indicative of disease progression and response to intervention, potentially yielding non-invasive diagnostic tools.

Moreover, the research sparks intriguing questions regarding dietary influence and lifestyle factors in modulating disease penetrance and progression in genetic ALS/FTD. The role of nutrition in neurodegenerative disease has long been debated, but Dubey and Bellen’s data provide a mechanistic foundation for considering specific fatty acid supplementation as part of a multifaceted therapeutic regimen.

Technological advances leveraged in this study, including state-of-the-art mass spectrometry for lipid profiling and CRISPR-based models, illustrate the power of modern biomedical tools in unraveling complex disease networks. The precise quantification of PUFA species and their spatial distribution within neurons enables a granular understanding of how these molecules interface with neurodegenerative processes at the molecular level.

In sum, Dubey and Bellen’s research spotlights polyunsaturated fatty acids as potent modulators of neuronal health in the context of C9orf72-associated ALS and FTD. The multifaceted mechanisms by which PUFAs exert neuroprotection underscore the potential for developing lipid-targeted therapeutics capable of altering disease trajectories. As the neuroscience community digests the profound implications of these findings, the prospect of harnessing dietary and pharmacologic interventions to combat incurable neurodegenerative diseases becomes increasingly tangible.

Future research directions inspired by this study will undoubtedly focus on delineating optimal PUFA species and formulations, exploring synergistic effects with other neuroprotective agents, and expanding investigations to broader patient cohorts. The integration of cutting-edge lipidomics with genetic and proteomic data promises a comprehensive framework for understanding and ultimately mitigating neurodegeneration.

As the global burden of ALS and FTD continues to rise, innovations such as this provide much-needed hope. The convergence of lipid biology and neurodegeneration heralds a new era of therapeutic discovery, spearheaded by insightful research that blends molecular detail with translational ambition. The full impact of Dubey and Bellen’s work will unfold in the years to come, potentially transforming the clinical landscape of these formidable diseases.

Subject of Research: Neuroprotective effects of polyunsaturated fatty acids in C9orf72-linked amyotrophic lateral sclerosis and frontotemporal dementia.

Article Title: A neuroprotective role of polyunsaturated fatty acids in C9orf72-ALS/FTD.

Article References:
Dubey, S.K., Bellen, H.J. A neuroprotective role of polyunsaturated fatty acids in C9orf72-ALS/FTD. Nat Neurosci 28, 710–712 (2025). https://doi.org/10.1038/s41593-025-01920-7

Image Credits: AI Generated